Molecular Partners AG ADR (MOLN) — Cash Flow-to-Debt Ratio
Molecular Partners AG ADR (MOLN) has a Cash Flow-to-Debt Ratio of -0.49x as of December 2025, meaning its operating cash flow of $-10.67 Million could theoretically repay 0% of its total liabilities ($21.77 Million) in one year. See Molecular Partners AG ADR free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Molecular Partners AG ADR Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Molecular Partners AG ADR across 13 annual periods. Also explore Molecular Partners AG ADR (MOLN) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Molecular Partners AG ADR (2013–2025)
Year-by-year debt coverage analysis for Molecular Partners AG ADR. For market capitalisation and broader financial context, see market cap of Molecular Partners AG ADR.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.35x | $-51.26 Million | $21.77 Million | ▲ +32.9% |
| 2024 | -3.51x | $-59.25 Million | $16.89 Million | ▼ -30.3% |
| 2023 | -2.69x | $-59.01 Million | $21.92 Million | ▼ -161.5% |
| 2022 | 4.38x | $118.57 Million | $27.09 Million | ▲ +414.6% |
| 2021 | -1.39x | $-90.95 Million | $65.38 Million | ▼ -285.6% |
| 2020 | -0.36x | $-28.98 Million | $80.33 Million | ▼ -1441.5% |
| 2019 | -0.02x | $-1.19 Million | $50.80 Million | ▲ +96.5% |
| 2018 | -0.67x | $-42.47 Million | $63.45 Million | ▲ +53.7% |
| 2017 | -1.45x | $-40.02 Million | $27.69 Million | ▼ -97.3% |
| 2016 | -0.73x | $-35.38 Million | $48.30 Million | ▼ -286.9% |
| 2015 | 0.39x | $26.50 Million | $67.60 Million | ▲ +257.5% |
| 2014 | -0.25x | $-11.33 Million | $45.54 Million | ▼ -13.0% |
| 2013 | -0.22x | $-13.61 Million | $61.80 Million | — |